mRNA 5′ Cap Analogs With Hydrophobic N6 Modification for Capping Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing mRNA 5′-end cap analogs have low capping efficiency, leading to unstable and translationally inactive uncapped mRNAs, which can induce an unwanted immune response and reduce translation efficiency, and are difficult to separate from capped mRNAs without enzymatic treatment.
Innovation Solution
Introduce a hydrophobic substituent at the N6-adenosine position of the trinucleotide or tetranucleotide cap analogue, allowing easy separation of capped and uncapped mRNAs using chromatographic methods and enhancing mRNA expression efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If dinucleotide cap analogs are used for in vitro transcription, then capping can be achieved, but capping efficiency is less than 100% and rarely exceeds 90%
Solution Approach 1:
The patent changes the structural parameters of the cap analog from a dinucleotide to a trinucleotide configuration. This structural parameter change fundamentally alters the incorporation kinetics, enabling near-complete capping efficiency (>99%) and eliminating the production of uncapped mRNA that would otherwise degrade and trigger immune responses.
2Reliability
If enzymatic treatment is used to remove uncapped mRNAs, then capped mRNA stability is improved, but process complexity increases
Solution Approach 1:
The patent extracts the problem of uncapped mRNA production at its source by using a trinucleotide cap analog that incorporates with near-100% efficiency. This eliminates the need for subsequent enzymatic treatment steps (5′-polyphosphatase and 5′-exonuclease) that would otherwise be required to remove uncapped mRNA, thereby simplifying the overall process while maintaining mRNA stability.
3Ease of operation
If hydrophobic substituent is introduced at N6-adenosine position, then separation of capped and uncapped mRNA becomes easy, but molecular structure complexity increases
Solution Approach 1:
The patent applies local quality modification by introducing a hydrophobic substituent specifically at the N6-adenosine position of the trinucleotide cap analog. This localized structural modification creates differential chromatographic behavior that enables easy separation of capped from uncapped mRNA, while the rest of the molecular structure remains compatible with natural mRNA processing.
4Productivity
If trinucleotide cap analogs are used, then capping efficiency increases to >99%, but cost of synthesis increases
Solution Approach 1:
The patent changes the nucleotide composition parameter from dinucleotide to trinucleotide, which increases capping efficiency to >99%. While this structural change increases synthesis complexity, the near-complete capping efficiency eliminates the need for costly enzymatic purification steps and reduces waste, providing an overall cost-effective solution for high-value mRNA applications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified cap analogs enable high-purity purification of capped mRNAs and significantly increase protein expression efficiency in eukaryotic cells, while maintaining compatibility with other cap modifications.
Implementation Method 1
allowing easy separation of capped and uncapped mRNAs by chromatographic methods
Data Source
AI summary
The invention relates to new mRNA 5′ end cap analogs, RNA molecules containing them, their uses and methods for their in vitro synthesis, as well as a method for protein or peptide synthesis in vitro or in cell cultures, which method encompasses translation of the RNA molecule.